Outlook Therapeutics (OTLK) Virtual Investor Closing Bell Series summary

Corporate overview and market opportunity

• Aims to enhance the standard of care in retina diseases with an ophthalmic formulation of bevacizumab, targeting wet AMD as the first indication.

• Recently secured first EU and UK authorizations for ophthalmic bevacizumab, with plans to expand into diabetic macular edema and branch retinal vein occlusion.

• The anti-VEGF retina market is valued at over $16 billion globally, with the US and Europe as primary markets.

• Completed enrollment in the final US clinical trial (NORSE-8) and expects to announce top-line results in Q4, aiming for FDA resubmission in Q1 next year.

• Physician research shows 82%-85% interest in a regulatory-approved ophthalmic bevacizumab, highlighting demand for an on-label product.

Differentiation and regulatory exclusivity

• Off-label bevacizumab, originally for oncology, does not meet ophthalmic requirements for particulates, endotoxins, and protein concentration.

• Repackaging for ophthalmic use reduces drug potency, leading to frequent patient switching to branded therapies.

• EU approval grants 10 years of market exclusivity; US approval would provide 12 years of regulatory exclusivity.

• No new IP protection, but exclusivity is based on regulatory approval as the first ophthalmic formulation.

Commercialization and partnerships

• Initial EU launch will focus on the UK and Germany to establish reference pricing, with further expansion planned.

• Exclusive partnership with Cencora for distribution, logistics, and regulatory support in both Europe and the US.

• Open to profit-sharing and joint commercialization partnerships, especially ex-US, to maximize shareholder value.

• Ongoing market access and health technology assessment work in lead EU markets.